A new drug trial is seeking pediatric and adult participants, age 6 to 70, who have dyskinetic cerebral palsy (DCP) — including chorea, athetosis, or dystonia — that causes involuntary movements that are difficult to control.
The Kinect-DCP clinical research study “is testing a study drug, called valbenazine, to determine if it is safe to use and if it helps to improve involuntary movements for individuals with DCP,” the project’s website said. The website added that compensation for time and travel may be available to participants.
To qualify, participants must have a confirmed diagnosis of dyskinesia due to cerebral palsy, and must not have involuntary movements due to conditions other than cerebral palsy.
The study will last approximately 56 weeks, divided into a six-week screening period; a 14-week double-blind treatment period; a two-week washout period (the first of two); a 32-week open-label treatment; and a second, two-week washout period.
Valbenazine is taken orally once a day and can be swallowed whole or can be sprinkled onto and swallowed with soft food. It can also be taken via gastronomy tube. During the first treatment period, half the participants will receive a placebo. During the second treatment period, all participants will be given valbenazine.
Visit the Kinect-DCP website for additional information. The Cerebral Palsy Foundation is also supporting study recruiting efforts.
